Transition from Ziprasidone IM to Oral Formulation in Agitated Patients with Acute Exacerbation of Schizophrenia: An Open Trial

Abstract

Introduction

A transition from IM to oral formulation of an antipsychotic agent is often required during the long-term management of schizophrenia. This multicenter trial evaluates the IM/oral sequential administration of ziprasidone in agitated subjects with an exacerbation of schizophrenia.

Methods

Adult patients requiring IM therapy for schizophrenic symptoms were assigned to IM ziprasidone 10 mg for 3 days, followed by oral ziprasidone (initial dose: 80 mg/day) for 8 weeks. The primary efficacy outcomes were the change in the total PANSS and in the CGI-S scores vs. baseline values.

Results

In total, 150 patients were included in the study. A decline in the PANSS and CGI-S scores was observed throughout the study (p<0.0001 vs. baseline): these reductions became significant at the point of transition from IM to oral formulation (p<0.0001 vs. baseline).

Discussion

Even with the limitations of any non-comparative study, these results suggest that the IM/oral sequential administration of ziprasidone is an effective and well tolerated therapeutic option in the management of acute exacerbations of schizophrenia in agitated patients.

Key words

acute exacerbation - antipsychotic agents - schizophrenia - transition - ziprasidone

• References

• 1 Lesem MD, Zajecka JM, Swift RH et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62: 12-18
• 2 Nordstrom K, Allen MH. Managing the acutely agitated and psychotic patient. CNS Spectr 2007; 12 (10 Suppl. 17) 5-11
• 3 Zimbroff DL, Allen MH, Battaglia J et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr 2005; 10: 1-15
• 4 Preval H, Klotz SG, Southard R et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005; 27: 140-144
• 5 Cañas F, Pérez-Solá V, Díaz S et al. ZIMO Trial Collaborative Group. Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial. Clin Drug Investig 2007; 27: 633-645
• 6 Brook S. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. J Clin Psychiatry 2003; 64 (Suppl. 19) 13-18
• 7 Gillies D, Beck A, McCloud A et al. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev 2005; 4: CD003079
• 8 Maguire GA. Comprehensive understanding of schizophrenia and its treatment. Am J Health Syst Pharm 2002; 59 (17 Suppl. 5) S4-S11
• 9 Cañas F. Management of agitation in the acute psychotic patient – efficacy without excessive sedation. Eur Neuropsychopharmacol 2007; 17 (Suppl. 02) S108-S114
• 10 Swainston Harrison T, Scott LJ. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. CNS Drugs 2006; 20: 1027-1052
• 11 Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007; 2: 137-177
• 12 Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000; 61: 933-941
• 13 Daniel DG, Potkin SG, Reeves KR et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155: 128-134
• 14 Daniel DG, Zimbroff DL, Swift RH et al. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol 2004; 19: 9-15
• 15 Brook S, Walden J, Benattia I et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005; 178: 514-523
• 16 Jangro WC, Preval H, Southard R et al. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. Child Adolesc Psychiatry Ment Health 2009; 3: 9
• 17 Rais AR, Williams K, Rais T et al. Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. Psychiatr (Edgmont) 2010; 7: 17-24
• 18 Shu L, Zhang H, Wang G et al. Intramuscular ziprasidone has improved tolerability over haloperidol and comparable efficacy for control of agitation in Chinese patient with schizophrenia. Schizophrenia International Research Society (SIRS) Congress 10–14 April 2010; Florence, Italy
• 19 Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911-936